EGFR and lung cancer: Regarding immune checkpoint inhibitors direct efficacy in Exon 20 insertion mutant lung cancers, data from retrospective studies suggested similar outcomes as compared to wild-type historical control, and better than classical EGFR mutant patient [8,9].